Career history of Claudia Ordonez
Former positions of Claudia Ordonez
| Companies | Position | Start | End |
|---|---|---|---|
| KEROS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2019-08-31 | 2021-07-29 |
| AKCEA THERAPEUTICS, INC. | Corporate Officer/Principal | 2018-10-31 | 2019-08-31 |
Flatley Discovery Lab LLC
 Flatley Discovery Lab LLC Miscellaneous Commercial ServicesCommercial Services Flatley Discovery Lab LLC performs medical research activities. The non-profit company is based in Charlestown, MA. | Chief Tech/Sci/R&D Officer | 2015-09-30 | 2018-09-30 |
| BIOGEN INC. | Chief Tech/Sci/R&D Officer | 2012-06-30 | 2015-09-30 |
| VERTEX PHARMACEUTICALS INCORPORATED | Chief Tech/Sci/R&D Officer | 2006-06-30 | 2012-05-31 |
Training of Claudia Ordonez
| University of Maryland | Undergraduate Degree |
| The University of California, San Francisco | Doctorate Degree |
Statistics
International
| United States | 8 |
Operational
| Chief Tech/Sci/R&D Officer | 4 |
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| BIOGEN INC. | Health Technology |
| KEROS THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Flatley Discovery Lab LLC
Flatley Discovery Lab LLC Miscellaneous Commercial ServicesCommercial Services Flatley Discovery Lab LLC performs medical research activities. The non-profit company is based in Charlestown, MA. | Commercial Services |
Akcea Therapeutics, Inc.
 Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Claudia Ordonez
- Experience
